India Glycols Limited Reschedules NCLT Meetings for Scheme of Arrangement to March 24, 2026

India Glycols Limited has announced the rescheduling of crucial National Company Law Tribunal (NCLT) ordered meetings related to its Scheme of Arrangement. The meetings, originally scheduled for March 9, 2026, have been moved to March 24, 2026, following approval from the NCLT Allahabad Bench at Prayagraj. Meeting Rescheduling Details The company filed an interim application seeking rescheduling due to the unavailability of the Hon'ble Chairperson appointed by the NCLT to chair the meetings on March 9, 2026. The NCLT, through its revised order dated February 16, 2026, granted permission for the meetings to be convened on the new date. Parameter: Details Original Date: March 9, 2026 Revised Date: March 24, 2026 Meeting Format: Video conferencing NCLT Order Date: February 16, 2026 Order Upload Date: February 18, 2026 Scheme of Arrangement Background The meetings are being conducted for the purpose of considering and approving the Scheme of Arrangement under Sections 230 to 232 of the Companies Act, 2013. The scheme involves three entities and their respective shareholders: India Glycols Limited (Applicant No. 1/Demerged Company) Ennature Biopharma Limited IGL Spirits Limited Meeting Participants and Process The NCLT has directed the convening of separate meetings for two distinct groups of stakeholders. Both meetings will be conducted through video conferencing to ensure broader participation and accessibility. Stakeholder Group: Meeting Purpose Equity Shareholders: Scheme approval consideration Unsecured Creditors: Scheme approval consideration Regulatory Compliance and Documentation The disclosure was made under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has made the NCLT order available on its website for stakeholder reference. The communication was addressed to both BSE Limited (Scrip Code: 500201) and National Stock Exchange of India Limited (Symbol: INDIAGLYCO). The company noted that a certified copy of the order is awaited, and the Scheme remains subject to applicable regulatory and other approvals. This rescheduling represents a procedural adjustment to accommodate the chairperson's availability while maintaining the integrity of the approval process for the proposed corporate restructuring. India Glycols Limited has delivered a robust financial performance in Q3FY26, demonstrating strong growth momentum across its diversified business portfolio. The company's Board of Directors approved the unaudited financial results for the quarter and nine months ended December 31, 2025, during their meeting held on February 10, 2026, as announced through a regulatory filing under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Strong Revenue and Profitability Growth The company reported impressive financial metrics for Q3FY26, with significant improvements in both revenue and profitability compared to the previous year. Financial Metric Q3FY26 Q3FY25 Growth (%) Revenue from Operations ₹2,551.06 crores ₹2,423.76 crores +5.25% Net Profit ₹65.26 crores ₹43.84 crores +48.87% EBITDA ₹177.16 crores ₹129.98 crores +36.30% Basic EPS ₹10.42 ₹7.08 +47.18% The company's EBITDA margin expanded significantly, reflecting improved operational efficiency and better cost management. Total expenses for the quarter stood at ₹2,462.67 crores compared to ₹2,371.13 crores in Q3FY25. Nine-Month Performance Highlights For the nine-month period ended December 31, 2025, India Glycols maintained its growth trajectory with consistent performance improvements. Nine-Month Metrics FY26 (9M) FY25 (9M) Growth (%) Revenue from Operations ₹7,464.80 crores ₹6,849.82 crores +8.98% Net Profit ₹172.05 crores ₹130.03 crores +32.34% EBITDA ₹486.67 crores ₹376.10 crores +29.40% Basic EPS ₹27.47 ₹21.00 +30.81% Segment-wise Performance Analysis India Glycols' diversified business model across four key segments contributed to the overall strong performance. The Potable Spirits segment remained the largest revenue contributor, while Bio-Fuel showed remarkable growth. Q3FY26 Segment Revenue: Segment Q3FY26 Revenue Q3FY25 Revenue Growth (%) Potable Spirits ₹1,793.46 crores ₹1,777.02 crores +0.93% Bio-Fuel ₹394.28 crores ₹271.54 crores +45.22% Bio-based Specialities ₹312.98 crores ₹325.13 crores -3.73% Ennature Biopharma ₹50.34 crores ₹50.07 crores +0.54% Segment Results (Profit Before Interest and Tax): Segment Q3FY26 Results Q3FY25 Results Growth (%) Bio-Fuel ₹32.99 crores ₹8.84 crores +273.19% Bio-based Specialities ₹41.13 crores ₹28.00 crores +46.89% Potable Spirits ₹72.43 crores ₹73.26 crores -1.13% Ennature Biopharma ₹2.04 crores ₹4.52 crores -54.87% Corporate Developments and Strategic Initiatives The company has undertaken several strategic initiatives during the period. The Board approved a demerger scheme involving the separation of Bio Pharma undertaking into Ennature Bio Pharma Limited and Spirits & Biofuel Undertaking into IGL Spirits Limited. The National Company Law Tribunal (NCLT) allowed the application on January 15, 2026, with the appointed date for the scheme being April 1, 2026. Corporate Action Details Preferential Allotment 51,03,765 equity shares at ₹915 per share Amount Raised ₹467 crores (November 2025) Stock Split Face value reduced from ₹10 to ₹5 (August 2025) NCLT Approval Date January 15, 2026 Demerger Appointed Date April 1, 2026 Exceptional Items and Regulatory Impact The company reported exceptional items of ₹0.83 crores during Q3FY26, related to additional employee benefit expenses arising from the implementation of New Labour Codes by the Government of India effective November 21, 2025. These codes consolidated multiple existing labour legislations into four unified frameworks. Consolidated Performance On a consolidated basis, India Glycols reported revenue from operations of ₹2,551.10 crores for Q3FY26, with net profit of ₹67.57 crores. The consolidated results include contributions from subsidiaries and joint venture Clariant IGL Specialty Chemicals Private Limited, which contributed ₹3.26 crores to the quarter's profit. The company's strong performance across multiple segments, successful capital raising, and strategic restructuring initiatives position it well for continued growth in the coming periods. Source: We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better. Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians. As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.